Abstract
Purpose: :
To asses the long-term effects of intravitreal bevacizumab as primary treatment in managing inflammatory choroidal neovascularization (CNV)
Methods: :
Sixteen consecutive patients with newly diagnosed inflammatory CNV treated with intravitreal injection of 1.25 mg of bevacizumab were reviewed retrospectively . Main outcome measure were : best corrected visual acuity , foveal thicknes measured by optical coherence tomography (OCT) and clinically completed resolution of CNV
Results: :
CNV resolved completely in 16/16 (100%) affected eyes.At the last examination ,visual acuity was improved in 14 eyes (87,5%),stable in 2 (12,5%) , and worse in 0 (0 %) eyes. Over a mean follow-up of 16.5 months (range 10 to 31 months), twelve eyes received one injection ,three eyes developed CNV recurrence and requires a second injection and 1 eye requires a third injection. Foveal thickness on OCT images decreased significantly (p= 0.049 ) after the treatment .
Conclusions: :
In this small series of eyes with long-term follow-up , intravitreal bevacizumab for inflammatory CNV was found to be safe and showed favourable visual outcomes for both subfoveal and juxtafoveal or extrafoveal inflammatory CNV.
Keywords: choroid: neovascularization • uveitis-clinical/animal model • vascular endothelial growth factor